Dupilumab Reduces Biomarkers of Type 2 Inflammation in Adult and Adolescent Patients With Eosinophilic Esophagitis: Results From Parts A and C of a Three-Part, Phase 3 LIBERTY EoE TREET Study
2022; Elsevier BV; Volume: 149; Issue: 2 Linguagem: Inglês
10.1016/j.jaci.2021.12.688
ISSN1097-6825
AutoresMarc E. Rothenberg, Ikuo Hirano, Evan S. Dellon, Margaret H. Collins, John Leung, Christoph Schlag, Alain Schoepfer, Qiong Zhao, Jennifer Maloney, Sivan Harel, Kiran Patel, Brad Shumel, Angela Khodzhayev, Ledia Goga, Juby A. Jacob‐Nara, Yamo Deniz, Paul Rowe, Elizabeth Laws, Bola Akinlade, Leda Mannent, Nikhil Amin, Danen Cunoosamy, Jennifer D. Hamilton,
Tópico(s)Eosinophilic Disorders and Syndromes
ResumoDupilumab, a fully human mAb, blocks the shared receptor component for IL-4/IL-13. Part A of 3-part, phase 3 LIBERTY-EoE-TREET (NCT03633617) demonstrated the efficacy/safety of weekly dupilumab 300mg vs placebo in adolescent/adult EoE patients for 24-weeks. For patients completing Part A, Part C was a 28-week extended active treatment period to evaluate efficacy/safety of weekly dupilumab 300mg for 52-weeks. This analysis assessed dupilumab effect on biomarkers of type 2 inflammation in Part C.
Referência(s)